Dosing and uses of Hypaque, RenoDIP (diatrizoate)
Adult dosage forms and strengths
uretral solution
- 30%
- 18% (dilute)
Retrograde Cystourethrography
Instill 25-300 mL into bladder depending on age of patient and degree of bladder irritability; amounts >300 mL may be used if bladder capacity allows; best results obtained when the bladder is filled with the contrast agent
Administration
After sterile catheterization, the bladder should be filled to capacity using suitable sterile administration set; avoid using excessive pressure; presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates bladder is fulL
Pediatric dosage forms and strengths
uretral solution
- 30%
- 18% (dilute)
Retrograde Cystourethrography
Instill 25-300 mL into bladder depending on age of patient and degree of bladder irritability; amounts >300 mL may be used if bladder capacity allows; best results obtained when the bladder is filled with the contrast agent
Administration
After sterile catheterization, the bladder should be filled to capacity using suitable sterile administration set; avoid using excessive pressure; presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates bladder is fulL
Hypaque, RenoDIP (diatrizoate) adverse (side) effects
Frequency not defined
Hypothyroidism or transient thyroid suppression
With intravasation of drug
- Anaphylactoid reactions manifested as edema of the face and glottis, respiratory distress, confusion or shock that can be fatal
Warnings
Contraindications
Hypersensitivity to diatrizoate
Intravascular or intrathecal use
Cautions
Personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents
Iodine sensitivity
Use intravascular techniques that minimize risk for extravasation
Use caution in hepatic impairment, heart failure, hypertension, multiple myeloma, hyperthyroidism, pheochromocytoma, renal impairment, sickle cell disease, subarachnoid hemorrhage, and thromboembolism
Pregnancy and lactation
Pregnancy category: C
Lactation: Excreted in breast milk, use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Hypaque, RenoDIP (diatrizoate)
Mechanism of action
Provides contrast enhancement of the bladder
